Payment overview · 2025
General Payments
$2,561.22
132 reported records · 20 companies
Healthcare provider profile · identity verified
Alex Meilan Lam, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · PEMBROKE PINES, FL · NPI 1275624264
Verified facts
What the public records show
CMS Open Payments records show Alex Meilan Lam, MD received $2,561.22 in general payments during 2025 across 132 reported records.
Amgen Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Benlysta, Orencia, Otezla, Prolia, Saphnelo.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Saphnelo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Orencia by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Remicade by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $473.72 | 18.5% | 28 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $333.39 | 13.0% | 17 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $297.39 | 11.6% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.69 | 8.7% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $215.54 | 8.4% | 15 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $208.14 | 8.1% | 13 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $131.37 | 5.1% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $126.59 | 4.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.20 | 4.8% | 6 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $107.98 | 4.2% | 4 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $66.98 | 2.6% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $60.89 | 2.4% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $42.71 | 1.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.23 | 1.4% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $24.14 | 0.9% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $20.84 | 0.8% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $19.62 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.71 | 0.7% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $15.63 | 0.6% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $15.46 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,561.22 | 132 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $297.39 | 13 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | Octapharma USA, Inc., PFIZER INC. | $230.74 | 11 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $215.54 | 15 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $208.14 | 13 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $182.06 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $176.40 | 8 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $151.33 | 7 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $131.37 | 5 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $126.59 | 4 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $123.20 | 6 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $107.98 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $97.39 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $87.05 | 7 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $82.12 | 4 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $66.98 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.59 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $52.78 | 4 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $34.31 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $31.58 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| XCELL Normalized: xcell |
Device | Bioventus LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 168 | exact normalized | Medicare Part D |
| SAPHNELO saphnelo |
2025 | Saphnelo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
168 | 107 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 211 | 79 |
| Prolia | Denosumab | 168 | 107 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 12 |
| Tramadol Hcl | Tramadol Hcl | 115 | 27 |
| Methotrexate | Methotrexate Sodium | 95 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 65 | 29 |
| Fentanyl | Fentanyl | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 20 |
| Calcitriol | Calcitriol | 46 | 16 |
| Leflunomide | Leflunomide | 46 | 15 |
| Gabapentin | Gabapentin | 41 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Folic Acid | Folic Acid | 29 | 13 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 22 | suppressed |
| Humira(Cf) Pen | Adalimumab | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 20 | suppressed |
| Orencia | Abatacept/Maltose | 20 | suppressed |
| Enbrel Mini | Etanercept | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Zoledronic Acid | Zoledronic Acid/Mannitol-Water | 17 | 17 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Remicade | Infliximab | 16 | suppressed |
| Tymlos | Abaloparatide | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Otrexup | Methotrexate/Pf | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Saphnelo | Anifrolumab-Fnia | 13 | suppressed |
| Actemra | Tocilizumab | 12 | suppressed |
| Actemra Actpen | Tocilizumab | 11 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,561.22 · 132 records | Amgen Inc. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, ENBREL, EVENITY, HYRIMOZ, KRYSTEXXA, Kineret, LUPKYNIS, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, Ocrevus Zunovo, PANZYGA, PEMGARDA, PROLIA, RINVOQ, SAPHNELO, SKYRIZI, TAVNEOS, TONMYA, TREMFYA, UPLIZNA, XCELL, XELJANZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error